Adaptive and innate immune responses to gene transfer vectors: Role of cytokines and chemokines in vector function

Gene Therapy

Volumn 10, Issue 11 SPEC., 2003, Pages 991-998

  Chen, D ^a   Murphy, B ^b,c   Sung, R ^b   Bromberg, J S ^a,b  

^a Carl C Ichan Center   (United States)

^b Recanati/Miller Transplantation Institute   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Chemokine; Cytokine; Gene therapy; Innate immunity

Indexed keywords

ADENOVIRUS VECTOR; CAPSID PROTEIN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CYTOKINE; DOUBLE STRANDED RNA; GAMMA INTERFERON; GUANINE NUCLEOTIDE BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 6; MACROGOL; MAJOR HISTOCOMPATIBILITY ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; NEUTRALIZING ANTIBODY; OLIGONUCLEOTIDE; PLASMID DNA; PROTEIN KINASE; RANTES; RIBONUCLEASE; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VIRUS DNA; VIRUS PROTEIN; VIRUS RECEPTOR; VIRUS RNA; VIRUS VACCINE; VIRUS ANTIGEN;

ADENOVIRUS; ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; GENE TRANSFER; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; ANIMAL; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; IMMUNOLOGY; INFLAMMATION; METHODOLOGY;

ADENOVIRIDAE; DNA VIRUSES; RNA VIRUSES;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, VIRAL; CHEMOKINES; CYTOKINES; GENE THERAPY; GENETIC VECTORS; HUMANS; INFLAMMATION; TRANSDUCTION, GENETIC;

EID: 0038128343     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302031     Document Type: Review

References (84)

1. Yang Y, Ertl HC, Wilson JM. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994; 1: 433-442.
2. Yang Y et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411.
3. Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnick N, Verma IM. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995; 92: 1401-5.
4. DeMatteo RP, Markmann JF, Kozarsky KF, Barker CF, Raper SE. Prolongation of adenoviral transgene expression in mouse liver by T lymphocyte subset depletion. Gene Therapy 1996; 3: 4-12.
5. Fisher KJ et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 1997; 3: 306-312.
6. Chirmule N et al. Role of E4 in eliciting CD4 T-cell and B-cell responses to adenovirus vectors delivered to murine and nonhuman primate lungs. J Virol 1998; 72: 6138-6145.
7. Chen HH et al. DNA from both high-capacity and first-generation adenoviral vectors remains intact in skeletal muscle. Hum Gene Ther 1999; 10: 365-373.
8. Kafri T et al. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci USA 1998; 95: 11377-11382.
9. Molinier-Frenkel V et al. Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes. J Virol 2000; 74: 7678-7682.
10. Molinier-Frenkel V et al. Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J Virol 2002; 76: 127-135.
11. Croyle MA, Chirmule N, Zhang Y, Wilson JM. 'Stealth' adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol 2001; 75: 4792-801.
12. Zhong L, Granelli-Piperno A, Choi Y, Steinman RM. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur J Immun 1999; 29: 964-972.
13. Lieber A et al. Inhibition of NF-kappaB activation in combination with bcl-2 expression allows for persistence of first-generation adenovirus vectors in the mouse liver. J Virol 1998; 72: 9267-9277.
14. Jooss K, Yang Y, Fisher KJ, Wilson JM. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998; 72: 4212-4223.
15. Porgador A et al. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med 1998; 188: 1075-1082.
16. Casares S et al. Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope. J Exp Med 1997; 186: 1481-1486.
17. Chattergoon MA, Robinson TM, Boyer JD, Weiner DB. Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen-presenting cells. J Immunol 1998; 160: 5707-5718.
18. Bouloc A et al. Immunization through dermal delivery of protein-encoding DNA: a role for migratory dendritic cells. Eur J Immunol 1999; 29: 446-454.
19. Brossart P et al. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol 1997; 158: 3270-3276.
20. Ballas ZK, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 1996; 157: 1840-1845.
21. Klinman DM et al. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 1996; 93: 2879-2883.
22. Scheule RK. The role of CpG motifs in immunostimulation and gene therapy. Adv Drug Deliv Rev 2000; 44: 119-134.
23. Yi AK et al. CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J Immunol 1998; 160: 4755-4761.
24. Macfarlane DE, Manzel L. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. J Immunol 1998; 160: 1122-1131.
25. Yi AK, Krieg AM. CpG DNA rescue from anti-IgM-induced WEHI-231 B lymphoma apoptosis via modulation of I kappa B alpha and I kappa B beta and sustained activation of nuclear factor-kappa B/c-Rel. J Immunol 1998; 160: 1240-1245.
26. Yi AK, Krieg AM. Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. J Immunol 1998; 161: 4493-4497.
27. Hacker H et al. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J 1998; 17: 6230-6240.
28. Yamamoto S, Kuramoto E, Shimada S, Tokunaga T. In vitro augmentation of natural killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from Mycobacterium bovis BCG. Jpn J Cancer Res 1988; 79: 866-873.
29. Yi AK, Chace JH, Cowdery JS, Krieg AM. IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. J Immunol 1996; 156: 558-564.
30. Weiner GJ et al. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 1997; 94: 10833-10837.
31. Roman M et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997; 3: 849-854.
32. Sun S, Zhang X, Tough DF, Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med 1998; 188: 2335-2342.
33. Chu RS et al. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 1997; 186: 1623-1631.
34. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001; 19: 65-91.
35. Medzhitov R, Janeway Jr CA. Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 1997; 9: 4-9.
36. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413: 732-738.
37. Paludan SR, Ellermann-Eriksen S, Kruys V, Mogensen SC. Expression of TNF-alpha by herpes simplex virus-infected macrophages is regulated by a dual mechanism: transcriptional regulation by NF-kappa B and activating transcription factor 2/ Jun and translational regulation through the AU-rich region of the 3′ untranslated region. J Immunol 2001; 167: 2202-2208.
38. Sato M et al. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction. Immunity 2000; 13: 539-548.
39. Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Annu Rev Immunol 2002; 20: 55-72.
40. Higginbotham JN, Seth P, Blaese RM, Ramsey WJ. The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid. Hum Gene Ther 2002; 13: 129-141.
41. Malmgaard L, Salazar-Mather TP, Lewis CA, Biron CA. Promotion of alpha/beta interferon induction during in vivo viral infection through alpha/beta interferon receptor/STAT1 system-dependent and -independent pathways. J Virol 2002; 76: 4520-4525.
42. Schnell MA et al. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther 2001; 3: 708-722.
43. Muruve DA, Barnes MJ, Stillman IE, Libermann TA. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther 1999; 10: 965-976.
44. Bowen GP et al. Adenovirus vector-induced inflammation: capsid-dependent induction of the C-C chemokine RANTES requires NF-kappa B. Hum Gene Ther 2002; 13: 367-379.
45. Tibbles LA et al. Activation of p38 and ERK signaling during adenovirus vector cell entry lead to expression of the C-X-C chemokine IP-10. J Virol 2002; 76: 1559-1568.
46. Borgland SL et al. Adenovirus vector-induced expression of the C-X-C chemokine IP-10 is mediated through capsid-dependent activation of NF-kappaB. J Virol 2000 ; 74: 3941-3947.
47. Hashimoto C, Hudson KL, Anderson KV. The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell 1988; 52: 269-279.
48. Nguyen MD, Julien JP, Rivest S. Innate immunity: the missing link in neuroprotection and neurodegeneration? Nat Rev Neurosci 2002; 3: 216-227.
49. Janeway Jr CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216.
50. Muzio M, Ni J, Feng P, Dixit VM. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 1997; 278: 1612-1615.
51. Cao Z et al. TRAF6 is a signal transducer for interleukin-1. Nature 1996; 383: 443-446.
52. Kopp E et al. ECSIT is an evolutionarily conserved intermediate in the Toll/IL-1 signal transduction pathway. Genes Dev 1999; 13: 2059-2071.
53. Clemens MJ, Elia A. The double-stranded RNA-dependent protein kinase PKR: structure and function. J Interferon Cytokine Res 1997; 17: 503-524.
54. Williams BR. PKR; a sentinel kinase for cellular stress. Oncogene 1999; 18: 6112-6120.
55. Terenzi F et al. The antiviral enzymes PKR and RNase L suppress gene expression from viral and non-viral based vectors. Nucleic Acids Res 1999; 27: 4369-4375.
56. Kumar M, Carmichael GG. Antisense RNA: function and fate of duplex RNA in cells of higher eukaryotes. Microbiol Mol Biol Rev 1998; 62: 1415-1434.
57. Smith GC, Jackson SP. The DNA-dependent protein kinase. Genes Dev 1999; 13: 916-934.
58. Karpova AY et al. Interferon regulatory factor-3 is an in vivo target of DNA-PK. Proc Natl Acad Sci USA 2002; 99: 2818-2823.
59. Daniel R, Katz RA, Skalka AM. A role for DNA-PK in retroviral DNA integration. Science 1999; 284: 644-647.
60. Boyer J, Rohleder K, Ketner G. Adenovirus E4 34k and E4 11k inhibit double strand break repair and are physically associated with the cellular DNA-dependent protein kinase. Virology 1999; 263: 307-312.
61. Sung RS, Qin L, Bromberg JS. TNFα and IFNγ induced by innate anti-adenoviral immune responses inhibit adenovirus-mediated transgene expression. Mol Ther 2001; 3: 757-767.
62. Qin L et al. Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression. Hum Gene Ther 1997; 8: 2019-2029.
63. Rollins BJ. Chemokines. Blood 1997; 90: 909-928.
64. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12: 121-127.
65. Luther SA, Cyster JG. Chemokines as regulators of T cell differentiation. Nat Immunol 2001; 2: 102-107.
66. Chen D et al. Adenoviral vectors stimulate potent chemokine expression in transplanted hearts. Mol Ther 2002; 5: s7 (abstract 19).
67. Otake K, Ennist DL, Harrod K, Trapnell BC. Nonspecific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses. Hum Gene Ther 1998; 9: 2207-2222.
68. Carter PJ, Samulski RJ. Adeno-associated viral vectors as gene delivery vehicles. Int J Mol Med 2000; 6: 17-27.
69. Zaiss AK et al. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol 2002; 76: 4580-4590.
70. Addison CL, Hitt M, Kunsken D, Graham FL. Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors. J Gen Virol 1997; 78: 1653-1661.
71. Brough DE et al. Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo. J Virol 1997; 71: 9206-9213.
72. Ritter T et al. Stimulatory and inhibitory action of cytokines on the regulation of hCMV-IE promoter activity in human endothelial cells. Cytokine 2000; 12: 1163-1170.
73. Qin L et al. Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression. Hum Gene Ther 1997; 8: 2019-2029.
74. Lucin P et al. Late phase inhibition of murine cytomegalovirus replication by synergistic action of interferon-gamma and tumour necrosis factor. J Gen Virol 1994; 75: 101-110.
75. Harms JS, Splitter GA. Interferon-gamma inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter. Hum Gene Ther 1995; 6: 1291-1297.
76. Gribaudo G et al. Interferons inhibit onset of murine cytomegalovirus immediate-early gene transcription. Virology 1993; 197: 303-311.
77. Presti RM et al. Interferon gamma regulates acute and latent murine cytomegalovirus infection and chronic disease of the great vessels. J Exp Med 1998; 188: 577-588.
78. Guidotti LG et al. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4: 25-36.
79. Ghazizadeh S, Carroll JM, Taichman LB. Repression of retrovirus-mediated transgene expression by interferons: implications for gene therapy. J Virol 1997; 71: 9163-9169.
80. Lui VW, Falo LD, Huang L. Systemic production of IL-12 by naked DNA mediated gene transfer: toxicity and attenuation of transgene expression in vivo. J Gene Med 2001; 3: 384-393.
81. Loser P, Jennings GS, Strauss M, Sandig V. Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFkappaB. J Virol 1998; 72: 180-190.
82. Hottiger MO, Felzien LK, Nabel GJ. Modulation of cytokine-induced HIV gene expression by competitive binding of transcription factors to the coactivator p300. EMBO J 1998; 17: 3124-3134.
83. Nagata K, Marban E, Lawrence JH, Donahue JK. Phosphodiesterase inhibitor-mediated potentiation of adenovirus delivery to myocardium. J Mol Cell Cardiol 2001; 33: 575-580.
84. Mesika A, Grigoreva I, Zohar M, Reich Z. A regulated NFkappaB-assisted import of plasmid DNA into mammalian cell nuclei. Mol Ther 2001; 3: 653-657.